Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Breast Cancer Research
  • View Item
  • Home
  • ICR Divisions
  • Breast Cancer Research
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Treating cancer with selective CDK4/6 inhibitors.

Thumbnail
View/Open
Accepted version (829.3Kb)
Publication Date
2016-07
ICR Author
Turner, Nicholas
O'Leary, Benjamin
Author
O'Leary, B
Finn, RS
Turner, NC
Type
Journal Article
Metadata
Show full item record
Abstract
Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at the heart of cancer as a pathological process. Clinical implementation of first-generation, nonselective CDK inhibitors, designed to inhibit this proliferation, was originally hampered by the high risk of toxicity and lack of efficacy noted with these agents. The emergence of a new generation of selective CDK4/6 inhibitors, including ribociclib, abemaciclib and palbociclib, has enabled tumour types in which CDK4/6 has a pivotal role in the G1-to-S-phase cell-cycle transition to be targeted with improved effectiveness, and fewer adverse effects. Results of pivotal phase III trials investigating palbociclib in patients with advanced-stage oestrogen receptor (ER)-positive breast cancer have demonstrated a substantial improvement in progression-free survival, with a well-tolerated toxicity profile. Mechanisms of acquired resistance to CDK4/6 inhibitors are beginning to emerge that, although unwelcome, might enable rational post-CDK4/6 inhibitor therapeutic strategies to be identified. Extending the use of CDK4/6 inhibitors beyond ER-positive breast cancer is challenging, and will likely require biomarkers that are predictive of a response, and the use of combination therapies in order to optimize CDK4/6 targeting.
URL
https://repository.icr.ac.uk/handle/internal/819
Collections
  • Breast Cancer Research
Licenseref URL
http://www.rioxx.net/licenses/all-rights-reserved
Version of record
10.1038/nrclinonc.2016.26
Subject
Humans
Neoplasms
Breast Neoplasms
Aminopyridines
Piperazines
Pyridines
Benzimidazoles
Purines
Cyclin D1
Antineoplastic Combined Chemotherapy Protocols
Cell Cycle
Forecasting
Female
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6
Clinical Trials as Topic
Molecular Targeted Therapy
Research team
Molecular Oncology
Language
eng
License start date
2016-07
Citation
Nature reviews. Clinical oncology, 2016, 13 (7), pp. 417 - 430

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.